Large-scale testing (Phase 3)WithdrawnNCT01860742What this trial is testingRandomized Phase III of PRRT Versus InterferonWho this might be right forGastro-intestinal Neuroendocrine Tumors Jules Bordet Institute
Not applicableNot Yet RecruitingNCT07538791What this trial is testingItalian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)Who this might be right forPheochromocytomasParagangliomas Azienda USL Reggio Emilia - IRCCS 210
Early research (Phase 1)WithdrawnNCT06411301What this trial is testingA Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin ReceptorsWho this might be right forMultiple Myeloma, RefractoryMultiple Myeloma in RelapseMultiple Myeloma Progression Jules Bordet Institute
Testing effectiveness (Phase 2)Looking for participantsNCT06456359What this trial is testingPasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell TumorWho this might be right forDesmoplastic Small Round Cell TumorSynovial Sarcoma University Hospital Heidelberg 28
Not applicableLooking for participantsNCT07195500What this trial is testingClinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/ParagangliomaWho this might be right forNeuroblastomaPheochromocytomaParaganglioma Nanjing First Hospital, Nanjing Medical University 30
Testing effectiveness (Phase 2)Study completedNCT02162446What this trial is testing68Ga-OPS202 Study for Diagnostic Imaging of GEP NETWho this might be right forGastroenteropancreatic Neuroendocrine Tumors Ipsen 12
Large-scale testing (Phase 3)UnknownNCT03252353What this trial is testingEfficacy and Safety of Octreotide Capsules (MYCAPSSA) in AcromegalyWho this might be right forAcromegaly Chiasma, Inc. 56
Early research (Phase 1)Active Not RecruitingNCT06379217What this trial is testingNEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.Who this might be right forMetastatic Neuroendocrine Prostate Cancer Novartis Pharmaceuticals 31
Not applicableStudy completedNCT02389101What this trial is testingMolecular and Whole-body MR Imaging in LymphomasWho this might be right forLymphomaHodgkin DiseaseLymphoma, Non-Hodgkin Turku University Hospital 21
Testing effectiveness (Phase 2)Looking for participantsNCT05278208What this trial is testingLutathera for Treatment of Recurrent or Progressive High-Grade CNS TumorsWho this might be right forHigh Grade GliomaMeningiomaEmbryonal Tumor+10 more Nationwide Children's Hospital 65
Testing effectiveness (Phase 2)Ended earlyNCT06939036What this trial is testingStudy of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )Who this might be right forSmall Cell Lung Cancer Extensive StageMerkel Cell Carcinoma Ariceum Therapeutics GmbH 2
Testing effectiveness (Phase 2)Looking for participantsNCT03145857What this trial is testingEvaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to UseWho this might be right forNeuroendocrine Tumors AHS Cancer Control Alberta 1,534
Large-scale testing (Phase 3)Study completedNCT01578239What this trial is testingA Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid TumoursWho this might be right forCarcinoid Tumor of the Small BowelNeuroendocrine Tumour Advanced Accelerator Applications 231
Early research (Phase 1)Ended earlyNCT00002947What this trial is testingIndium In 111 Pentetreotide in Treating Patients With Refractory CancerWho this might be right forBrain and Central Nervous System TumorsChildhood Langerhans Cell HistiocytosisGastrointestinal Carcinoid Tumor+9 more Yale University 35
Large-scale testing (Phase 3)Study completedNCT00442533What this trial is testingSafety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine TumorsWho this might be right forNeuroendocrine Tumors Radio Isotope Therapy of America 200
Not applicableNo Longer AvailableNCT01980732What this trial is testing68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive TumorsWho this might be right forCarcinoid TumorsIslet Cell (Pancreatic NET)Other Neuroendocrine Tumors Andrei Iagaru
Very early researchUnknownNCT02817945What this trial is testingDual SSTR2 and Integrin αvβ3 Targeting PET/CT ImagingWho this might be right forLung CancerNeuroendocrine Neoplasm Peking Union Medical College Hospital 100
Not applicableStudy completedNCT02810600What this trial is testingStudy to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin ReceptorsWho this might be right forNeuroendocrine Tumors Centre de recherche du Centre hospitalier universitaire de Sherbrooke 2,120
Testing effectiveness (Phase 2)Looking for participantsNCT06840821What this trial is testingEvaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin ReceptorsWho this might be right forAdvanced Solid Tumors Mainline Biosciences (Shanghai) Co., Ltd 156
Testing effectiveness (Phase 2)Looking for participantsNCT06982300What this trial is testingSSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPCWho this might be right forNasopharyngeal Carcinoma (NPC) University Medical Center Groningen 10